ESTA Stock Forecast 2025-2026
Distance to ESTA Price Targets
ESTA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Establishment Labs (ESTA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ESTA and similar high-potential opportunities.
Latest ESTA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ESTA has a bullish consensus with a median price target of $58.00 (ranging from $42.00 to $62.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $39.92, the median forecast implies a 45.3% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESTA Analyst Ratings
ESTA Price Target Range
Latest ESTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $52.00 |
| Feb 27, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $52.00 |
| Oct 14, 2024 | BTIG | Marie Thibault | Buy | Maintains | $65.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $50.00 |
| Aug 22, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $45.00 |
| Aug 7, 2024 | JP Morgan | Allen Gong | Overweight | Maintains | $50.00 |
| Aug 7, 2024 | Stephens & Co. | George Sellers | Overweight | Reiterates | $68.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $50.00 |
| Jun 6, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $70.00 |
| May 22, 2024 | Citigroup | Joanne Wuensch | Neutral | Downgrade | $60.00 |
| Apr 3, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $60.00 |
| Apr 1, 2024 | Mizuho | Anthony Petrone | Buy | Reiterates | $65.00 |
| Mar 12, 2024 | TD Cowen | Joshua Jennings | Outperform | Maintains | $60.00 |
| Feb 29, 2024 | JP Morgan | Allen Gong | Overweight | Maintains | $53.00 |
| Jan 11, 2024 | Stephens & Co. | George Sellers | Overweight | Reiterates | $47.00 |
| Nov 9, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $50.00 |
| Nov 8, 2023 | Mizuho | Anthony Petrone | Buy | Maintains | $50.00 |
| Nov 8, 2023 | TD Cowen | Outperform | Maintains | $0.00 | |
| Aug 31, 2023 | JP Morgan | Allen Gong | Overweight | Initiates | $75.00 |
Establishment Labs Holdings Inc. (ESTA) Competitors
The following stocks are similar to Establishment Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Establishment Labs Holdings Inc. (ESTA) Financial Data
Establishment Labs Holdings Inc. has a market capitalization of $1.15B with a P/E ratio of 0.0x. The company generates $166.02M in trailing twelve-month revenue with a -51.0% profit margin.
Revenue growth is +41.0% quarter-over-quarter, while maintaining an operating margin of -41.9% and return on equity of -236.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Establishment Labs Holdings Inc. (ESTA) Business Model
About Establishment Labs Holdings Inc.
Produces innovative breast implants and body shaping products.
The company designs, develops, manufactures, and markets high-quality medical devices, particularly breast implants. It generates revenue through the sale of its proprietary Motiva Implants, which are recognized for their advanced features that enhance patient safety and satisfaction.
Headquartered in Alajuela, Costa Rica, the company has a strong presence in global markets, especially in Latin America, Europe, and Asia. Establishment Labs is focused on advancing standards in aesthetics and reconstruction surgeries, contributing to the growth of the medical technology sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,018
CEO
Mr. Filippo Caldini
Country
Costa Rica
IPO Year
2018
Website
www.establishmentlabs.comEstablishment Labs Holdings Inc. (ESTA) Latest News & Analysis
Establishment Labs (NASDAQ: ESTA) will present five-year follow-up data from the Motiva US IDE Study on breast augmentation, led by Medical Director Dr. Caroline Glicksman.
Five-year follow-up data from the Motiva US IDE Study could impact product credibility and market demand, influencing Establishment Labs' stock performance and growth potential in women's health.
Establishment Labs® (NASDAQ: ESTA) has partnered with Meghan Trainor following the FDA approval of Motiva Implants®, focusing on women's health in breast aesthetics and reconstruction.
Establishment Labs' partnership with a high-profile celebrity like Meghan Trainor enhances brand visibility and credibility, potentially boosting sales of Motiva Implants and positively impacting stock performance.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will hold its Q4 2024 Earnings Conference Call on February 26, 2025, at 4:30 PM ET, featuring key company executives and analysts.
The upcoming earnings call for Establishment Labs provides key insights into financial performance and future guidance, influencing investor sentiment and stock valuation.
Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance
1 month agoEstablishment Labs Holdings reported Q4 revenue of $44.5 million, matching prior guidance, and reaffirmed its outlook for 2025. The company focuses on women's health, particularly breast aesthetics.
Establishment Labs' steady revenue and reaffirmed 2025 guidance signal stability and growth potential, crucial for investor confidence and stock performance.
Establishment Labs Holdings Inc. (ESTA) reported a quarterly loss of $0.98 per share, worse than the estimated loss of $0.62, and compared to a loss of $0.79 per share a year prior.
Establishment Labs' larger-than-expected quarterly loss signals worsening financial performance, potentially impacting investor confidence and stock valuation.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025, with CEO Juan José Chacón-Quirós and CFO Raj Denhoy presenting.
Establishment Labs' participation in a major healthcare conference highlights its commitment to growth and visibility, potentially influencing investor confidence and stock performance.
Frequently Asked Questions About ESTA Stock
What is Establishment Labs Holdings Inc.'s (ESTA) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Establishment Labs Holdings Inc. (ESTA) has a median price target of $58.00. The highest price target is $62.00 and the lowest is $42.00.
Is ESTA stock a good investment in 2025?
According to current analyst ratings, ESTA has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $39.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESTA stock?
Wall Street analysts predict ESTA stock could reach $58.00 in the next 12 months. This represents a 45.3% increase from the current price of $39.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Establishment Labs Holdings Inc.'s business model?
The company designs, develops, manufactures, and markets high-quality medical devices, particularly breast implants. It generates revenue through the sale of its proprietary Motiva Implants, which are recognized for their advanced features that enhance patient safety and satisfaction.
What is the highest forecasted price for ESTA Establishment Labs Holdings Inc.?
The highest price target for ESTA is $62.00 from at , which represents a 55.3% increase from the current price of $39.92.
What is the lowest forecasted price for ESTA Establishment Labs Holdings Inc.?
The lowest price target for ESTA is $42.00 from at , which represents a 5.2% increase from the current price of $39.92.
What is the overall ESTA consensus from analysts for Establishment Labs Holdings Inc.?
The overall analyst consensus for ESTA is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $58.00.
How accurate are ESTA stock price projections?
Stock price projections, including those for Establishment Labs Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
